A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer
Status:
Recruiting
Trial end date:
2023-09-09
Target enrollment:
Participant gender:
Summary
The researchers are doing this study to find out whether the study drug onapristone ER,
combined with the standard treatment for your cancer (letrozole and palbociclib), is a safe
treatment for people who have metastatic or unresectable ER+/PR+/HER2- breast cancer. The
researchers will test different doses of the study drug to find the highest dose that causes
few or mild side effects.